| You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily
NanoViricides (NYSE: NNVC) is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape! Bird flu is a dangerous virus that has been making many headlines in recent months. A pandemic is not inevitable, scientists say. But the outbreak has passed worrisome milestones in recent weeks. People have become increasingly aware of how dangerous viruses can be, including Bird flu. This puts the spotlight on emerging tiny biotech firm NanoViricides, Inc. (NYSE: NNVC), a company that is revolutionizing antiviral drug where viruses are unlikely to escape! NNVC’s broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. This could be groundbreaking in what may become another pandemic. A vaccine against a rapidly changing virus is a game of chasing a rapidly moving target, as we have all learned from the experience during the COVID-19 pandemic. It is thus clear that a drug that the virus cannot escape is the only appropriate tool to fight a potential pandemic and NNVC has developed such a drug! NV-387 is a broad-spectrum antiviral that mimics the very host-side features that the virus continues to require no matter how much it changes in the field. It is highly unlikely that a susceptible virus would escape such a drug. Notably NV-387 has demonstrated substantially superior activity to existing influenza drugs in a lethal lung infection animal study. NNVC recently announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline. The Company has previously stated that it is working towards a Phase II clinical trial to evaluate the effectiveness of NV-387 for the treatment of MPox patients. MPox disease, caused by the human Mpox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the African region. Hundreds of millions of dollars of taxpayer money have gone towards ineffective antiviral drugs that do NOT work against MPox/Smallpox! Discover how NNVC’s broad-spectrum antiviral drug NV-387 is poised to cause a revolution in treatment of viral diseases and could lead to tremendous shareholder value. Small Caps Daily We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,500 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 02/24/2025.
| 